PharmAla Biotech Holdings Inc. announced that it had entered into a binding sales agreement with Numinus Wellness Inc. to provide its GMP LaNeo? MDMA for a prospective clinical trial.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.19 CAD | 0.00% | -5.00% | +35.71% |
05-03 | PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy | MT |
04-23 | Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla | CI |
1st Jan change | Capi. | |
---|---|---|
+35.71% | 12.07M | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.30% | 21.93B | |
-12.15% | 22.34B | |
-5.38% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- MDMA Stock
- News Pharmala Biotech Holdings Inc.
- Pharmala Biotech Holdings Inc. Signs Sale Agreement with Numinus